amifostine anhydrous has been researched along with Lymphoma, Non-Hodgkin in 13 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Lymphoma, Non-Hodgkin: Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the radiation dose-response relationship on salivary dysfunction and quality of life (QOL) over time in patients with lymphoma receiving radiation therapy (RT) to the head and neck (H&N)." | 2.74 | A prospective study of salivary gland function in lymphoma patients receiving head and neck irradiation. ( Hickey, G; Killion, L; Martin, C; Mauch, PM; Ng, AK; Rodrigues, NA; Silver, B; Stevenson, MA, 2009) |
| "Thirty-five patients (20 with non-Hodgkin lymphoma, 12 with Hodgkin disease, and 3 with acute myelogenous leukemia) who underwent autologous stem cell transplantation were conditioned with total body irradiation 2 Gy twice daily on days -8 through -6; cyclophosphamide 6 g/m(2), etoposide 1." | 2.71 | Cytoprotection by amifostine during autologous stem cell transplantation for advanced refractory hematologic malignancies. ( Gabriel, DA; Harvey, D; Kirby, SL; Krasnov, C; Moore, DT; Serody, JS; Shea, TC, 2005) |
| "Amifostine can be given safely at a dose of 910 mg/m2 four times in 1 day in combination with HD-CTX." | 2.70 | Phase I-II study of escalating doses of amifostine combined with high-dose cyclophosphamide. ( Bosshard, M; Cavalli, F; Egger, HP; Gabutti, L; Ghielmini, M; Kiess, M; Pampallona, S; Sessa, C; Van der Bosch, S, 2001) |
| " One patient died after the first CHOP administration because of anthracycline-related acute cardiomyopathy (corresponding to a toxic death rate of 2." | 2.70 | Influence of amifostine on toxicity of CHOP in elderly patients with aggressive non-Hodgkin's lymphoma--a phase II study. ( Budach, V; Eucker, J; Genvresse, I; Krüger, L; Lange, C; Possinger, K; Schweigert, M; Sezer, O; Späth-Schwalbe, E, 2002) |
| "Transient hypotension was the most common side effect occurring in association with amifostine." | 1.31 | Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study. ( Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 9 (69.23) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rodrigues, NA | 1 |
| Killion, L | 1 |
| Hickey, G | 1 |
| Silver, B | 1 |
| Martin, C | 1 |
| Stevenson, MA | 1 |
| Mauch, PM | 1 |
| Ng, AK | 1 |
| Gómez, HL | 1 |
| Samanéz, C | 1 |
| Campana, F | 1 |
| Neciosup, SP | 1 |
| Vera, L | 1 |
| Casanova, L | 1 |
| Leon, J | 1 |
| Flores, C | 1 |
| de Mendoza, FH | 1 |
| Casteñeda, CA | 1 |
| Pinto, JA | 1 |
| Vallejos, CS | 1 |
| Phillips, GL | 1 |
| Meisenberg, BR | 1 |
| Reece, DE | 1 |
| Adams, VR | 1 |
| Badros, AZ | 1 |
| Brunner, JL | 1 |
| Fenton, RG | 1 |
| Filicko, J | 1 |
| Grosso, DL | 1 |
| Hale, GA | 1 |
| Howard, DS | 1 |
| Johnson, VP | 1 |
| Kniska, A | 1 |
| Marshall, KW | 1 |
| Mookerjee, B | 1 |
| Nath, R | 1 |
| Rapoport, AP | 1 |
| Sarkodee-Adoo, C | 1 |
| Takebe, N | 1 |
| Vesole, DH | 1 |
| Wagner, JL | 1 |
| Flomenberg, N | 1 |
| Gabriel, DA | 1 |
| Shea, TC | 1 |
| Serody, JS | 1 |
| Moore, DT | 1 |
| Kirby, SL | 1 |
| Harvey, D | 1 |
| Krasnov, C | 1 |
| Li, QB | 1 |
| Tang, XQ | 1 |
| Zhao, ZG | 1 |
| Wang, HX | 1 |
| You, Y | 1 |
| Chen, ZC | 1 |
| Zou, P | 1 |
| Cagnoni, PJ | 1 |
| Jones, RB | 1 |
| Bearman, SI | 1 |
| Ross, M | 1 |
| Hami, L | 1 |
| Franklin, WA | 1 |
| Capizzi, R | 1 |
| Schein, PS | 1 |
| Shpall, EJ | 1 |
| Poloni, A | 1 |
| Leoni, P | 1 |
| Curzi, L | 1 |
| Cantori, I | 1 |
| Mancini, S | 1 |
| Montanari, M | 1 |
| Masia, MC | 1 |
| Olivieri, A | 1 |
| De Souza, CA | 1 |
| Santini, G | 1 |
| Marino, G | 1 |
| Nati, S | 1 |
| Congiu, AM | 1 |
| Vigorito, AC | 1 |
| Damasio, E | 1 |
| Genvresse, I | 2 |
| Lange, C | 2 |
| Schanz, J | 1 |
| Schweigert, M | 2 |
| Harder, H | 1 |
| Possinger, K | 2 |
| Späth-Schwalbe, E | 2 |
| Ghielmini, M | 1 |
| Van der Bosch, S | 1 |
| Bosshard, M | 1 |
| Pampallona, S | 1 |
| Gabutti, L | 1 |
| Egger, HP | 1 |
| Kiess, M | 1 |
| Cavalli, F | 1 |
| Sessa, C | 1 |
| Emmanouilides, C | 1 |
| Territo, M | 1 |
| Andrey, J | 1 |
| Mason, J | 1 |
| Krüger, L | 1 |
| Eucker, J | 1 |
| Sezer, O | 1 |
| Budach, V | 1 |
| Coia, L | 1 |
| Krigel, R | 1 |
| Hanks, G | 1 |
| Comis, R | 1 |
| Algazy, K | 1 |
| Peters, R | 1 |
| McCulloch, W | 1 |
| Schien, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I/II Study of Escalating Dose Melphalan With Autologous Pluripotent Hematopoietic Stem Cell Support and Amifostine Cytoprotection in Cancer Patients[NCT00003425] | Phase 1/Phase 2 | 25 participants (Anticipated) | Interventional | 1997-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 trials available for amifostine anhydrous and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
A prospective study of salivary gland function in lymphoma patients receiving head and neck irradiation.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, | 2009 |
Addition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma: a phase II trial showing reduction in toxicity without altering long-term survival.
Topics: Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamid | 2012 |
Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma.
Topics: Adult; Amifostine; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Female; Hematopoiet | 2004 |
Cytoprotection by amifostine during autologous stem cell transplantation for advanced refractory hematologic malignancies.
Topics: Acute Disease; Adolescent; Adult; Amifostine; Cytoprotection; Female; Graft Survival; Hematopoietic | 2005 |
Use of amifostine in bone marrow purging.
Topics: Adult; Amifostine; Bone Marrow Purging; Bone Marrow Transplantation; Breast Neoplasms; Cyclophospham | 1996 |
Amifostine (WR-2721), a cytoprotective agent during high-dose cyclophosphamide treatment of non-Hodgkin's lymphomas: a phase II study.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Agents, Alkylating; Cyclophosphamide; Cytoprotection; | 2000 |
Phase I-II study of escalating doses of amifostine combined with high-dose cyclophosphamide.
Topics: Adolescent; Adult; Aged; Amifostine; Antineoplastic Agents, Alkylating; Bone Marrow; Cyclophosphamid | 2001 |
A randomized phase II study of amifostine used as stem cell protectant in non-hodgkin lymphoma patients receiving cisplatin-based salvage chemotherapy prior to stem cell transplant.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; He | 2001 |
Influence of amifostine on toxicity of CHOP in elderly patients with aggressive non-Hodgkin's lymphoma--a phase II study.
Topics: Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamid | 2002 |
A phase I study of WR-2721 in combination with total body irradiation (TBI) in patients with refractory lymphoid malignancies.
Topics: Amifostine; Combined Modality Therapy; Drug Evaluation; Humans; Leukemia, Lymphocytic, Chronic, B-Ce | 1992 |
3 other studies available for amifostine anhydrous and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
[Role of amifostine against the effect of etoposide on non-Hodgkin lymphoma bone marrow derived mesenchymal stem cells: an in vitro experiment].
Topics: Adult; Amifostine; Antigens, CD; Apoptosis; Bone Marrow Cells; Cell Proliferation; Cell Separation; | 2007 |
Ex vivo pharmacological purging of leukapheresis collections with nitrogen mustard: amifostine pretreatment improves both early and late peripheral blood progenitor cell recovery.
Topics: Amifostine; Animals; Bone Marrow Purging; Cell Survival; Cells, Cultured; Colony-Forming Units Assay | 1999 |
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Com | 2001 |